Published on 15.02.11 in Vol 13, No 1 (2011): Jan-Mar
Packaging and Labeling of Pharmaceutical Products Obtained from the Internet
Background: For patients, the prescription container label may be the only source of instructions on how to take their medicines. In the United States, the legal requirements for a prescription label are set by federal law and state statutes. The container should be comparable to that which manufacturers use to package drug products and should preserve a product’s identity, strength, quality, and purity and prevent contamination. Safety features such as a child-resistant closure should be provided. Pharmaceutical products purchased from international online pharmacies are not approved by the Food and Drug Administration (FDA) and may not meet US guidelines for labeling and packaging.
Objective: The study objective was to determine whether commonly purchased pharmaceutical products obtained from international online pharmacies are comparable to products dispensed in the United States with regard to labeling and packaging.
Methods: During March 2006 through January 2007, 41 pharmaceutical oral dosage form samples were obtained from international Internet pharmacy websites for evaluation: 18 generic simvastatin samples, 18 generic amlodipine samples, and 5 generic sildenafil samples. Contents for each package were observed and recorded and comparison of the prescription labeling and packaging of these products was made with prescription labeling and packaging requirements in the United States.
Results: Of the 41 drug products obtained from online pharmacies from 12 different countries, only 1 product (from Canada) would meet both labeling and packaging guidelines for products dispensed in the United States. Of those not meeting the requirements, 7 were dispensed in paper envelopes with label affixed that was either handwritten or typed and contained missing information such as name and address of dispenser, name of prescriber, name of patient, and directions for use. Another 3 products did not have a label affixed to the drug product, but information was printed on a paper document enclosed in the shipping package, while 28 products did not have labels affixed to the drug product. In all, 39 of the 41 drug products’ packaging would not meet the US guidelines. Aside from the Canadian product, only 1 product from Mexico was dispensed in a container that would meet guidelines established in the United States. In total, 35 products were not dispensed in plastic vials but were dispensed in unit dose packages, paper envelopes with loose dosage forms, blister packs of drugs held together with rubber bands, or a combination of these packaging forms.
Conclusions: Results suggest that labeling and packaging standards for international generic drug products are not equivalent to labeling and packaging standards in the United States. This suggests dissimilar and substandard distribution processes compared with those in the United States, which in turn presents a challenge to patient comprehension and health literacy and may affect patient adherence to drug treatment regimens. These findings have strong implications for drug product quality, patient outcomes, therapeutic effectiveness, and safety.
J Med Internet Res 2011;13(1):e22)
For patients, the prescription container label may be the only source of instructions on how to take their medicines . According to the United States Pharmacopeia (USP),
the term “labeling” designates all labels and other written, printed, or graphic matter upon an immediate container of an article or upon, or in, any package or wrapper in which it is enclosed, except any outer shipping container. The term “label” designates that part of the labeling upon the immediate container .
In other words, “labeling” can refer to drug products from a manufacturer, and “label” can apply to drug products dispensed by a pharmacist on a prescription order.
In the United States, the legal requirements for a prescription label are set by federal law and state statutes [, ]. At the federal level, the required items of information for the prescription product label can be found in Section 503 (b) (2) of the Federal Food, Drug, and Cosmetic Act ( ) [ ]. States may have additional labeling requirements required by law [ ].
The National Association of Boards of Pharmacy (NABP) provides recommendations for state statutes on required items of information for outpatient prescription labels . These recommendations augment federal requirements and include such items as name (proprietary or generic) and strength of drug product dispensed, special requirements with regard to the name of the product if an equivalent drug product is dispensed, name of the manufacturer or distributor of the product dispensed, beyond-use date of the product, quantity dispensed, number of refills, and name or initial of the dispensing pharmacist.
In the United States, it is the professional responsibility of pharmacists to label the dispensed drug product with the items stated in the federal law in addition to any state requirements for the state in which he or she is practicing.
In addition to proper labeling, pharmacists should select packaging that maintains the integrity of the drug product. The pharmacist’s choice of container should be based primarily on the type and quantity of medication to be dispensed and manner of use . The container should be comparable to that which manufacturers use to package drug products and should preserve a product’s identity, strength, quality, and purity and prevent contamination. The type of container to be used by a pharmacist when dispensing a prescription drug is found in the manufacturer’s prescription product’s labeling and is regulated by the US Food and Drug Administration (FDA). The FDA regulation does not apply to products intended to be dispensed in the manufacturer’s original container. Manufacturer’s packaging and storage information is generally found on the original container or in the package insert.
In addition to packaging requirements for dispensing drug products, special consideration should be made for the closure on the prescription container. The closure must inhibit penetration of moisture and contaminants that can have a deleterious effect on oral dosage forms. A well-known example in pharmaceutics is the breakdown of aspirin into acetic acid and salicylic acid in the presence of moisture.
If the original package is intended to go directly from the pharmacist to the patient, manufacturers must place prescription drugs in child-resistant packages. Similarly, pharmacists must dispense prescription drugs for oral use to the patient in containers with child-resistant safety closures unless the patient or prescriber specifically requests otherwise.
A request for a safety container that is not child resistant must be obtained by the patient as a signed waiver and may apply to all of a patient’s dispensed medications. The pharmacist must maintain a record of the signed waiver request. Exceptions exist to these requirements, such as packaging of oral contraceptives because of their functional design, and certain types of cardiac drugs, such as nitroglycerin. In these instances, patients may need immediate access to the medication.
In addition, the closure must comply with guidelines specified in the Poison Prevention Packaging Act 1970 . This federal law was enacted as a result of reports of a significant number of accidental poisonings of children after ingestion of household chemicals, including medications. Closures that must comply with these safety guidelines include both legend and over-the-counter (OTC) drug products.
Often, prescription drugs are sold in bottles with a seal that must be removed the first time the bottle is opened. This is an example of “tamper-evident” packaging that was introduced in the 1980s. The design of tamper-evident packaging makes it apparent if the packaging has been previously opened. The Tylenol crisis of 1982 highlighted the need for manufacturers to provide safeguards to altering drug product packaging .
In general, pharmaceutical products purchased from international online pharmacies are unapproved by the FDA, and in addition to possibly not meeting standards of formulation, may not meet quality standards for labeling and packaging . International online pharmacies may offer convenience and potential cost savings to consumers, but potential health risks exist to patients from these types of drug purchases [ , ].
Currently, there is a paucity of information on packaging and labeling of pharmaceutical products imported via the Internet. The Office of Compliance in FDA’s Center for Drug Evaluation and Research initiated a study to determine the quality of a select group of pharmaceutical products purchased via the Internet from foreign sources. Packaging was a significant problem with virtually all of the Internet purchase samples. Many had either no or minimal labeling information for proper use. Some drug samples were shipped loosely in unlabeled plastic bags .
This paper reports on the variability of labeling and packaging for drug products obtained via the Internet. The objective of this study was to determine whether commonly purchased pharmaceutical products obtained from international online pharmacies are comparable to products dispensed in the United States with regard to labeling and packaging. This information is valuable for identifying trends in drug quality that may exist with consumer drug importation via the Internet.
Website Identification and Sample Acquisition
Drug product acquisition and website attributes were described previously in a report on drug quality, and a similar process was followed for this study . For all other drug product samples, searches of the World Wide Web were conducted with the browser Internet Explorer 6.0. The websites for the Internet pharmacies were located by using the advanced search options of Google (http://www.google.com). The keywords selected for entry into the query box of the browser included the search terms “generic simvastatin,” “generic amlodipine,” generic sildenafil,” “online pharmacies,” and “Internet pharmacy.” All proprietary forms of oral drug products were identified on the websites for prospective procurement. Our perspective was that of a consumer seeking to purchase these prescription medications online or comparison price shopping. For Internet drug purchases, a consumer credit card was used for financial transactions as specified on the websites. Prescription requirements were noted, and for drug products requiring a prescription (ie, products obtained from Canada), a prescription was issued by a physician from the Texas Tech University Health Sciences Center School of Medicine and faxed to the Internet pharmacy as specified on the website.
Upon receipt of drug product samples, the contents for each package were observed and recorded, and data were organized in tabular format. Comparison was made between the shipped items and prescription labeling and packaging requirements in the United States. Any additional distinguishing qualities were noted.
Website Identification and Sample Acquisition
During March 2006 through January 2007, simvastatin, amlodipine, and sildenafil drug product samples were purchased from international markets from 41 websites. A checklist of attributes was created for each specific drug product ().
Label and package characteristics of pharmaceutical products obtained from the Internet are presented in.
Deviation from US federal requirements for prescription labels and manufacturer requirements for prescription packaging are noted. Among all samples obtained, significant variation was observed in external package appearance, labeling of drug product (if any), and packaging of dispensed product.
Of the 41 drug products obtained, only 1 product from Canada would meet both labeling and packaging guidelines for products dispensed in the United States. In all, 4 products from Canada were labeled in a manner that would meet US guidelines, and although the Canadian products were packaged in similar containers to those dispensed in the United States, 3 of 4 containers were not child resistant, and no offer was made to patients to dispense in this manner on the websites. A total of 7 products were dispensed in paper envelopes with a label affixed that was either handwritten or typed and contained missing information such as name and address of dispenser, name of prescriber, name of patient, and directions for use. Another 3 products did not have a label affixed to the drug product, but information was printed on a paper document enclosed in the shipping package. In all, 28 products did not have labels affixed to the drug product, while 39 of the 41 drug products’ packaging would not meet guidelines established in the United States. Aside from the Canadian product, only 1 product from Mexico was dispensed in a container that woul meet US guidelines. Of the 41 products, 35 were not dispensed in plastic vials but were dispensed in unit dose packages, paper envelopes with loose dosage forms, blister packs of drugs held together with rubber bands or staples, or a combination of these packaging forms.
Results of this study indicate that drug products sold on the Internet—often accessible to consumers without prescription—present insufficient labeling and packing characteristics compared with products dispensed in the United States For example, picutred inis a tablet formulation of generic sildenafil (“Suhagra-100”) obtained from URL: http://www.viagrageneric.tripod.com. The tablets are ordinary in appearance, scored, contain no external markings with color variation from the US innovator product. Contents were packaged in unit dose plastic with foil backing, and the product appears to be from a legitimate drug manufacturer with manufacturer’s labeling. The shipping source was India as indicated from the international postal service packaging.
Of the 41 drug products, 36 did not meet criteria for prescription drug labeling, and 39 did not meet criteria for prescription drug containers and packaging as required in the United States. For all international products, the only drug products that met US standards for labeling were those from Canada. Only 1 container from Canada and 1 container from Mexico met US guidelines. No relationship could be ascertained between packaging standards and prescription requirements.
Comparison With Prior Work
Our findings corroborate a report by Westenberger et al, where drug sample packaging was a significant concern for virtually all of the Internet purchased samples . In this report, several samples had either no or minimal labeling information for proper usage or testing of these drugs. For instance, some samples had packaging with labeling in foreign languages, and others were shipped loosely in unlabeled plastic bags.
Medication errors have been attributed to improper labeling and packaging of medications. A major report from the Institute of Medicine (IOM) noted that problems with prescription drug labeling were cited as the cause of a large number of outpatient medication errors and adverse drug events (ADEs) . In addition, the United States Pharmacopeia (USP) found that 33% of the reports to its voluntary Medication Errors Reporting (MER) database cited labeling or packaging as having contributed to a medication error, including almost 30% of the fatalities reported [ ]. Some of the more common sources of medication errors are confusion between soundalike medication names or look-alike medication names and confusion due to similar appearances for medication packages or similar labels for different medications.
Patients may unintentionally misuse a prescribed medicine because of misunderstanding of instructions. Individuals who manage complex medication regimens were found to be at greater risk for making errors in interpreting container label instructions, particularly the elderly with limited literacy skills. The patient’s ability to understand prescription label instructions can be critical to safe use of medications since other sources of information on medicines for patients may not be adequate and pharmacists may not always have the opportunity to provide counseling to patients on prescribed medications .
Research in health literacy underscores the high prevalence of misunderstanding of seemingly simple instructions and warnings placed on prescription container labels by patients. Studies have demonstrated that the literacy level of patients has an impact on their ability to understand directions on a label . Health literacy has increasingly been viewed as a patient safety issue, and lower literacy may contribute to medication errors [ ]. Lower literacy and a greater number of prescription medications were independently associated with misunderstanding the instructions on prescription medication labels [ ]. Prescription drug labels should use explicit dosing intervals and clear and simple language within a patient-friendly label format—unlike the drug products received from the Internet as demonstrated in this study. Although health literacy levels of Internet drug buyers is largely unknown, it is reasonable to assume that they are not dissimilar to all patients in the population.
In addition to literacy and drug product labeling, of equal importance are the drug product’s container and packaging, not only to preserve the product’s integrity, but to provide ease of use for both pharmacist and patient . It has been demonstrated that patients actually prefer types of packaging and labeling that are designed for safety, are easier to read, and have better organized warnings with larger type size [ ].
Studies suggest that certain patient groups such as the elderly may benefit from specialized packaging for drug products . Providing medications in a package that identifies the day each dose is intended to be taken and provides information on proper self-administration can improve treatment regimen adherence and treatment outcomes in elderly patients. Certain patient groups may need the most attention to their packaging needs, yet this study suggests that these needs are unlikely to be met if drugs are purchased via the Internet.
Drugs obtained from international markets via the Internet can present a health risk to patients for a variety of reasons . This study has demonstrated that it is highly likely that the average US consumer may obtain an imported drug product from an Internet pharmacy website that does not meet quality specifications of packaging and labeling equivalent to US-dispensed products—another potential safety risk.
In the United States, policies and legislation are directed toward ensuring minimal health risk to patients in the use of prescription drugs, as reported by the US Food and Drug Administration . This report illustrates that consumers can obtain prescription drugs via the Internet without direct oversight from a health care professional. It has been stated that this ability to purchase medications directly from a website poses the greatest risk of drug adverse effects by bypassing the traditional “visit to the physician and a review by a pharmacist” [ ], and this observation may be expanded to included issues of packaging and labeling. Consumers who order drugs from the Internet do not have sufficient access to information and advice at the point of ordering and on delivery to make informed decisions about their safe and appropriate use [ ]. Again, substandard packaging and labeling may compound this risk.
This study has shown that a variety of packaging and labeling exists for pharmaceuticals obtained via the Internet. Based on the findings of this study, Canadian drug products dispensed are in many respects similar if not identical to US products, with similar prescription requirements . Perhaps further distinction should be made by health care authorities between drugs imported from international markets in general and from Canadian manufacturers.
The relatively small sample size in this study may not be wholly representative of all drugs sold on the Internet and generalizing our findings to other drugs should be done with a degree of caution. However, our findings corroborate previously published work, and further studies are warranted to identify trends in quality for Internet drug product labeling and packaging.
A goal of this study was to assess quality attributes that may indirectly convey information on safety and effectiveness through packaging and labeling properties. Many factors contribute to quality of packaging and labeling and although significant, the list of attributes observed in this study was not exhaustive. Until a direct association between packaging and labeling of Internet drug products and clinical outcomes is established, again, one must interpret these findings with some reservation.
Our findings indicate nonequivalent labeling and packaging for drug products available to consumers via the Internet compared with prescription drug products sold in the United States. These findings suggest dissimilar and substandard distribution processes compared with the United States, which in turn offer a greater challenge to patient comprehension and health literacy and may affect patient adherence to drug treatment regimens. In the United States, consumers need to be aware that, irrespective of advertising claims on Internet pharmacy websites, consumers may receive a drug product that is not equivalent to the US. counterpart and that may be dissimilar to products that would be allowed for consumers in the United States. These findings have strong implications for drug product quality, patient outcomes, therapeutic effectiveness, and safety that should be considered by clinicians to potentially safeguard patients who choose to purchase foreign-produced drugs via the Internet.
The author wishes to thank the Texas Affiliate of the American Heart Association for their financial support in the preparation of this research report.
Conflicts of Interest
- Wolf MS, Parker RM. A Health Literacy and Medication Safety Initiative. American College of Physicians Foundation. 2007. Improving Prescription Drug Container Labeling in the United States URL: http://www.acpfoundation.org/files/medlabel/acpfwhitepaper.pdf [accessed 2010-06-15] [WebCite Cache]
- Thompson JE, Davidow LW. Chapter 2, Labeling Prescriptions and Medications. In: Davidow LW, editor. A Practical Guide to Contemporary Pharmacy Practice. Baltimore, MD: Williams & Wilkins, A Waverly Company; 1998:2.1-2.4.
- US Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, 21 USC 353 Sec 503 (b) (2). URL: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm108068.htm [WebCite Cache]
- National Association of Boards of Pharmacy. August. 2008. Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy URL: http://www.nabp.net/ [accessed 2010-06-15] [WebCite Cache]
- Philadelphia College of Pharmacy and Science. Remington: The Science and Practice of Pharmacy. 21st Edition. Baltimore, MD: Lippincott Williams & Wilkins; 2006:1829-1833.
- US Consumer Product Safety Commission. US Consumer Product Safety Commission.: US Consumer Product Safety Commission; 2005. Poison Prevention Packaging: A Guide for Healthcare Professionals URL: http://www.cpsc.gov/cpscpub/pubs/384.pdf [accessed 2010-06-15] [WebCite Cache]
- Lockhart H, Paine FA. Packaging of Pharmaceuticals and Healthcare Products. London: Chapman and Hall; 1996.
- US Food and Drug Administration. US Food and Drug Administration. Unapproved Drugs: Drugs Marketed in the United States That Do Not Have Required FDA Approval. FDA's Concerns About Unapproved Drugs. URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm [accessed 2010-06-15] [WebCite Cache]
- Henney JE. Cyberpharmacies and the role of the US Food And Drug Administration. J Med Internet Res 2001;3(1):E3 [FREE Full text] [CrossRef] [Medline]
- Eysenbach G. Online prescribing of sildanefil (Viagra) on the world wide web. J Med Internet Res 1999;1(2):E10 [FREE Full text] [CrossRef] [Medline]
- Westenberger BJ, Ellison CD, Fussner AS, Jenney S, Kolinski RE, Lipe TG, et al. Quality assessment of internet pharmaceutical products using traditional and non-traditional analytical techniques. Int J Pharm 2005 Dec 8;306(1-2):56-70. [CrossRef] [Medline]
- Veronin MA, Nguyen NT. Comparison of simvastatin tablets from the US and international markets obtained via the Internet. Ann Pharmacother 2008 May;42(5):613-620. [CrossRef] [Medline]
- Berman A. J Med Syst. 2004 Feb. Reducing medication errors through naming, labeling, and packaging URL: http://portal.acm.org/citation.cfm?id=976716 [accessed 2010-12-06] [WebCite Cache]
- Schommer JC, Pedersen CA, Doucette WR, Gaither CA, Mott DA. Community pharmacists' work activities in the United States during 2000. J Am Pharm Assoc (Wash) 2002;42(3):399-406. [Medline]
- Davis TC, Wolf MS, Bass PF, Thompson JA, Tilson HH, Neuberger M, et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med 2006 Dec 19;145(12):887-894. [Medline]
- Soller RW, Lightwood JM. Comparison of the packaging and labeling of Target ClearRx with conventional prescription drug packaging and labeling. J Am Pharm Assoc (2003) 2007 Aug;47(4):484-490. [CrossRef] [Medline]
- Wolf MS, Davis TC, Shrank W, Rapp DN, Bass PF, Connor UM, et al. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns 2007 Aug;67(3):293-300. [CrossRef] [Medline]
- Schneider PJ, Murphy JE, Pedersen CA. Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc (2003) 2008 Feb;48(1):58-63. [CrossRef] [Medline]
- Eysenbach G. Online prescriptions of pharmaceuticals: where is the evidence for harm or for benefit? A call for papers--and for reflection. J Med Internet Res 2001 Mar;3(1):e1 [FREE Full text] [Medline] [CrossRef]
- Armstrong K, Schwartz JS, Asch DA. Direct sale of sildenafil (Viagra) to consumers over the Internet. N Engl J Med 1999 Oct 28;341(18):1389-1392. [CrossRef] [Medline]
- Veronin MA, Youan BB. Medicine. Magic bullet gone astray: medications and the Internet. Science 2004 Jul 23;305(5683):481. [CrossRef] [Medline]
- Veronin MA. Canadian Internet pharmacies: price, policy, and perspective. Res Social Adm Pharm 2007 Jun;3(2):236-248. [CrossRef] [Medline]
|ADE: adverse drug event|
|FDA: Food and Drug Administration|
|IOM: Institute of Medicine|
|MER: Medication Errors Reporting|
|NABP: National Association of Boards of Pharmacy|
|OTC: over the counter|
|USP: United States Pharmacopeia|
Edited by G Eysenbach; submitted 30.12.09; peer-reviewed by E Mahe, R Levaggi; comments to author 03.03.10; revised version received 21.06.10; accepted 29.06.10; published 15.02.11
©Michael Veronin. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 15.02.2011.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.